Core Insights - ENvue Medical has signed a distribution agreement with U-Deliver to expand access to its ENFit Syringes across non-acute care channels nationwide [1][2] - The partnership aims to enhance ENvue's presence in the non-acute enteral care market, focusing on providing reliable and safe solutions for feeding and medication delivery [2] Company Overview - ENvue Medical, Inc. specializes in intelligent, non-invasive solutions for enteral care in clinical and home care settings, headquartered in Tyler, Texas [4] - The company has a research and development presence in Tel-Aviv and Nesher, Israel, and operates two distinct technology platforms [4] Product Details - ENvue's ENFit Syringes are available in sizes of 2.5 mL, 5 mL, 10 mL, and 60 mL, and do not require a prescription [2] - The syringes meet ISO 80369-3 global standards and can be reused for up to seven days or 20 uses, ensuring safe enteral delivery [2] Partner Overview - U-Deliver is a U.S.-based supplier focused on enteral feeding supplies for home and long-term care settings, serving non-acute care customers through online and distribution channels [3]

Core Insights - ENvue Medical, Inc. has launched a new line of over-the-counter ENFit Syringes aimed at enhancing enteral care in both clinical and home settings, addressing the need for reliable and high-quality solutions as care shifts beyond hospitals [1][2] Product Launch - The ENFit Syringes are designed for feeding and medication delivery, available in sizes of 2.5 mL, 5 mL, 10 mL, and 60 mL, and will be sold without a prescription through online retailers like Amazon [2] - These syringes comply with ISO 80369-3 global standards and can be reused for up to seven days or 20 uses, promoting safe and consistent enteral delivery [2] Company Overview - ENvue Medical specializes in intelligent, non-invasive solutions for enteral care, with headquarters in Tyler, Texas, and R&D facilities in Tel-Aviv and Nesher, Israel [3] - The company focuses on two technology platforms: the ENvue Navigation Platform for minimally invasive feeding tube placement and acoustic-based therapeutic technologies like PainShield® and UroShield® [4]

Core Viewpoint - ENvue Medical, Inc. will ring the Nasdaq Opening Bell on January 14, 2026, marking a significant milestone for the company in the medical technology sector [1][3]. Company Overview - ENvue Medical, Inc. specializes in non-invasive therapeutic systems, including enteral access solutions and non-opioid pain management [1][4]. - The company is headquartered in Tyler, Texas, with research and development facilities in Tel-Aviv and Nesher, Israel [4]. Leadership and Ceremony Details - The ceremony will be led by Doron Besser, MD, the CEO of ENvue Medical, along with the leadership team, directors, employees, and key stakeholders [2][3]. - The event will take place at Nasdaq MarketSite in Times Square, New York, from 8:30 A.M. to 9:45 A.M. ET [3]. Technology Platforms - ENvue Medical operates two distinct technology platforms: the ENvue™ Navigation Platform and acoustic-based therapeutic technologies [4][5]. - The ENvue™ Navigation Platform is a minimally invasive electromagnetic navigation system for placing feeding tubes, which has received FDA 510(k) clearance for adult use [5]. - Acoustic-based technologies, such as PainShield® and UroShield®, utilize proprietary low-intensity surface acoustic wave technology for pain treatment and bacterial colonization reduction [5].

Core Insights - ENvue Medical's UroShield® Kit has been included in the UK NHS Drug Tariff Part IX, allowing for nationwide prescription reimbursement, which is expected to significantly enhance market access and demand for the product [1][3] - The company has received an initial purchase order from Peak Medical, indicating early commercial interest following the reimbursement decision [2][3] - The UroShield® Kit is designed to reduce catheter-associated urinary tract infections (CAUTIs) and blockages, addressing a significant healthcare challenge in the UK where catheter prevalence is approximately 6-7% in long-term care populations [3][6] Company Overview - ENvue Medical, Inc. specializes in non-invasive therapeutic systems and is headquartered in Tyler, Texas, with R&D facilities in Israel [5] - The company focuses on acoustic-based therapeutic technologies, including the UroShield® Kit, which utilizes proprietary low-intensity surface acoustic wave technology [5] Market Context - The inclusion of the UroShield® Kit in the NHS Drug Tariff Part IX represents a critical reimbursement milestone, removing barriers to access and enabling scalable NHS prescribing [3] - The partnership with Peak Medical is expected to enhance the distribution of the UroShield® Kit across UK hospitals and community settings, reflecting a commitment to improving patient outcomes [2][3]